167 related articles for article (PubMed ID: 15596044)
1. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis.
Iwaki H; Kageyama S; Isono T; Wakabayashi Y; Okada Y; Yoshimura K; Terai A; Arai Y; Iwamura H; Kawakita M; Yoshiki T
Cancer Sci; 2004 Dec; 95(12):955-61. PubMed ID: 15596044
[TBL] [Abstract][Full Text] [Related]
2. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine.
Kageyama S; Isono T; Iwaki H; Wakabayashi Y; Okada Y; Kontani K; Yoshimura K; Terai A; Arai Y; Yoshiki T
Clin Chem; 2004 May; 50(5):857-66. PubMed ID: 14764641
[TBL] [Abstract][Full Text] [Related]
3. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma.
Kageyama S; Isono T; Matsuda S; Ushio Y; Satomura S; Terai A; Arai Y; Kawakita M; Okada Y; Yoshiki T
Int J Urol; 2009 May; 16(5):481-6. PubMed ID: 19389084
[TBL] [Abstract][Full Text] [Related]
4. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
[TBL] [Abstract][Full Text] [Related]
5. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer.
Shabayek MI; Sayed OM; Attaia HA; Awida HA; Abozeed H
Pathol Oncol Res; 2014 Oct; 20(4):859-66. PubMed ID: 24696417
[TBL] [Abstract][Full Text] [Related]
7. A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis.
Lu CM; Lin JJ; Huang HH; Ko YC; Hsu JL; Chen JC; Din ZH; Wu YJ
BMC Cancer; 2014 May; 14():363. PubMed ID: 24884814
[TBL] [Abstract][Full Text] [Related]
8. A multi-analyte assay for the non-invasive detection of bladder cancer.
Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
[TBL] [Abstract][Full Text] [Related]
9. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.
Urquidi V; Goodison S; Ross S; Chang M; Dai Y; Rosser CJ
J Urol; 2012 Dec; 188(6):2377-83. PubMed ID: 23088986
[TBL] [Abstract][Full Text] [Related]
11. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.
Ebbing J; Mathia S; Seibert FS; Pagonas N; Bauer F; Erber B; Günzel K; Kilic E; Kempkensteffen C; Miller K; Bachmann A; Rosenberger C; Zidek W; Westhoff TH
World J Urol; 2014 Dec; 32(6):1485-92. PubMed ID: 24378824
[TBL] [Abstract][Full Text] [Related]
12. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer.
Diamandis EP
Clin Chem; 2004 May; 50(5):793-5. PubMed ID: 15105344
[No Abstract] [Full Text] [Related]
13. Multiplex protein signature for the detection of bladder cancer in voided urine samples.
Rosser CJ; Ross S; Chang M; Dai Y; Mengual L; Zhang G; Kim J; Urquidi V; Alcaraz A; Goodison S
J Urol; 2013 Dec; 190(6):2257-62. PubMed ID: 23764080
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
15. Urinary protein biomarker panel for the detection of recurrent bladder cancer.
Rosser CJ; Chang M; Dai Y; Ross S; Mengual L; Alcaraz A; Goodison S
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1340-5. PubMed ID: 24714076
[TBL] [Abstract][Full Text] [Related]
16. Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder.
Srivastava AK; Singh PK; Rath SK; Dalela D; Goel MM; Bhatt ML
Tumour Biol; 2014 Nov; 35(11):11435-42. PubMed ID: 25123267
[TBL] [Abstract][Full Text] [Related]
17. Detection of bladder cancer using a point-of-care proteomic assay.
Grossman HB; Messing E; Soloway M; Tomera K; Katz G; Berger Y; Shen Y
JAMA; 2005 Feb; 293(7):810-6. PubMed ID: 15713770
[TBL] [Abstract][Full Text] [Related]
18. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of urinary molecular markers in bladder cancer.
Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
[TBL] [Abstract][Full Text] [Related]
20. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
